dm+d

Unassigned

New Medicines

Haemophilia A in adults and adolescents with or without inhibitors

Information

New molecular entity
Novo Nordisk
Novo Nordisk

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A next-generation coagulation factor VIII (FVIII) mimetic antibody that potently enhances coagulation
It affects 1:4,000 to 1:5,000 live male births worldwide. It is five times as common as haemophilia B (factor IX deficiency) [1].
Haemophilia A in adults and adolescents with or without inhibitors
Subcutaneous injection